Logo image of CMMB

CHEMOMAB THERAPEUTICS LTD (CMMB) Stock Analyst Ratings

NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD

1.4  +0.03 (+2.56%)

After market: 1.4 0 (0%)

Buy % Consensus

84

ChartMill assigns a Buy % Consensus number of 84% to CMMB. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 9.18. This target is 555.71% above the current price.
CMMB was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CMMB.
In the previous month the buy percentage consensus was at a similar level.
CMMB was analyzed by 9 analysts. More opinions would make the average more meaningful.
CMMB Historical Analyst RatingsCMMB Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -71 -64 -57 -50 -43 -36 -29 -22 -15 -8 -1 2 4 6 8

Price Target & Forecast

Price Low Median Mean High 1.407.079.189.1811.55 - 405.00% 555.71% 555.71% 725.00%
CMMB Current Analyst RatingCMMB Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4
Up and Down Grades
Date Firm Action Rating
2025-05-16 Oppenheimer Maintains Outperform -> Outperform
2025-02-20 Maxim Group Maintains Buy -> Buy
2024-11-15 Oppenheimer Reiterate Outperform -> Outperform
2024-05-13 Maxim Group Initiate Buy
2024-05-06 Oppenheimer Upgrade Perform -> Outperform
2024-03-08 Oppenheimer Maintains Perform -> Perform
2023-12-19 Roth MKM Reiterate Buy
2023-10-06 Roth MKM Initiate Buy
2023-06-07 Oppenheimer Downgrade Outperform -> Perform
2023-04-18 Oppenheimer Maintains Outperform
2022-03-10 Oppenheimer Maintains Outperform
2021-12-07 Aegis Capital Initiate Buy
2021-05-26 Cantor Fitzgerald Initiate Overweight
2021-05-07 Oppenheimer Initiate Outperform